Skip to content
An Initiative of AVAC
Search
Back to Resource Library

Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of PrEP for Pregnant and Breastfeeding People

19 September 2023

Elimination of vertical transmission of HIV will require expanded access to HIV prevention strategies, such as PrEP, for pregnant and breastfeeding people.

Guidance from the World Health Organization (WHO) supports provision of HIV pre-exposure prophylaxis (PrEP) to pregnant and breastfeeding people (PBFP) who are at continuing substantial risk of HIV infection. Evidence has shown that people have an increased need for HIV prevention during pregnancy and the postnatal period, and that people who become infected with HIV during pregnancy or the postnatal period have a higher chance of transmitting HIV to their infants as compared to people who became infected with HIV before becoming pregnant.

To better understand the extent to which PrEP has been included in national prevention strategies for vertical transmission in MOSAIC countries, MOSAIC reviewed the current status of PrEP inclusion for PBFP in national vertical transmission policies, including prevention of mother to child transmission (PMTCT) or elimination of mother to child transmission (eMTCT) policies, across eight MOSAIC-supported countries (Eswatini, Kenya, Lesotho, Namibia, South Africa, Uganda, Zambia, and Zimbabwe). Findings from this review are summarized in the brief titled “Rapid Landscape Analysis of National Vertical Transmission Policies for Inclusion of HIV Pre-exposure Prophylaxis for Pregnant and Breastfeeding People.”

Topic(s): Normative Guidance/Policies, Service Delivery

Product(s): Cabotegravir, Multipurpose Prevention Technologies, Oral PrEP

Population(s): Pregnant and Lactating Populations

Format(s): Report

Source(s): MOSAIC

Type: Document

Download

Featured Resources

Document

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

External Link

Initiation and Continued Use of Oral Pre-Exposure Prophylaxis among Pregnant and Postpartum Women in South Africa (PrEP-PP): A demonstration cohort study

This article from The Lancet HIV describes the results of a demonstration study in South Africa, PrEP-PP, to integrate oral PrEP provision into public clinics offering antenatal and postnatal care to pregnant and lactating people.
External Link

Acceptability of Six-Monthly PrEP Dispensing Supported with Interim HIV Self-Testing to Simplify PrEP Delivery in Kenya: Findings from qualitative research

This article from BMC Health Services Research discusses the results of a pilot in Kenya to explore the acceptability of dispensing PrEP twice a year, with interim HIV self-testing, versus quarterly, with clinic-based HIV testing.
Document

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.
External Link

Dynamic Choice HIV Prevention with Cabotegravir Long-acting Injectable in Rural Uganda and Kenya: A randomised trial extension

This article from The Lancet HIV discusses the results of the SEARCH dynamic choice study conducted in Kenya and Uganda, comparing outcomes between one group offered a choice between oral PrEP, post-exposure prophylaxis, and cabotegravir for PrEP, and a second group receiving the standard of care.
External Link

Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A longitudinal qualitative study from a crossover trial in South Africa, Uganda, and Zimbabwe

This article from AIDS and Behavior explores South African, Ugandan, and Zimbabwean adolescent girls and young women’s experiences in a crossover trial of two HIV prevention products: daily oral PrEP and a monthly dapivirine vaginal ring.
Spreadsheet

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…
External Link

Role of HIV Self-testing in Strengthening HIV Prevention Services

This article from The Lancet HIV examines the potential role of HIV self-testing (HIVST) in achieving HIV prevention goals by looking at trials of use of HIVST with prevention tools such as pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and voluntary medical male circumcision (VMMC).
External Link

We Choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe

This article from PLOS One describes decision-making and product choice amongst adolescent girls and young women in South Africa, Uganda, and Zimbabwe when given a choice between oral PrEP and the dapivirine vaginal ring as part of the REACH crossover study.
External Link

“I was given PrEP, but had no privacy”: Mystery shopper perspectives of PrEP counseling for adolescent girls and young women in Kisumu County, Kenya

This article from PLOS One describes the results of a study using adolescent girls and young women as “mystery shoppers” in Kenya to identify barriers to effective PrEP service provision.